Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Novel MASP-2 inhibitors developed via directed evolution of human TFPI1 are potent lectin pathway inhibitors.

Szakács D, Kocsis A, Szász R, Gál P, Pál G.

J Biol Chem. 2019 May 17;294(20):8227-8237. doi: 10.1074/jbc.RA119.008315. Epub 2019 Apr 5.

2.

L-Selectin Expression is Influenced by Phosphatase Activity in Chronic Lymphocytic Leukemia.

Beke Debreceni I, Szász R, Kónya Z, Erdődi F, Kiss F, Kappelmayer J.

Cytometry B Clin Cytom. 2019 Mar;96(2):149-157. doi: 10.1002/cyto.b.21771. Epub 2019 Feb 6.

PMID:
30729673
3.

Effectiveness of the Combination of Rituximab and Standard Chemotherapeutic Regimens in Previously Untreated Patients with Chronic Lymphocytic Leukaemia in Real-Life: Results from a Noninterventional Study (CILI Study).

Szász R, Altai E, Pál K, Dombi P, Iványi J, Jakucs J, Jóni N, Illés Á, Tárkányi I, Szerafin L, Nagy Z, Farkas P, Nagy Á, Piukovics K, Ujj G, Schneider T.

Pathol Oncol Res. 2019 Apr;25(2):535-540. doi: 10.1007/s12253-018-0474-9. Epub 2018 Oct 25.

4.

Dasatinib inhibits coated-platelet generation in patients with chronic myeloid leukemia.

Mezei G, Debreceni IB, Kerenyi A, Remenyi G, Szasz R, Illes A, Kappelmayer J, Batar P.

Platelets. 2018 Aug 1:1-8. doi: 10.1080/09537104.2018.1501470. [Epub ahead of print]

PMID:
30067428
5.

MASP-3 is the exclusive pro-factor D activator in resting blood: the lectin and the alternative complement pathways are fundamentally linked.

Dobó J, Szakács D, Oroszlán G, Kortvely E, Kiss B, Boros E, Szász R, Závodszky P, Gál P, Pál G.

Sci Rep. 2016 Aug 18;6:31877. doi: 10.1038/srep31877.

6.

[Drug treatment of acute myelogenous leukaemia. Current options and future perspectives].

Telek B, Rejtő L, Batár P, Miltényi Z, Reményi G, Simon Z, Ujj Z, Mezei G, Szász R, Kiss A, Udvardy M, Illés Á.

Orv Hetil. 2016 May 29;157(22):843-8. doi: 10.1556/650.2016.30433. Review. Hungarian.

PMID:
27211353
7.

[Differential diagnosis of Graves' orbitopathy. Case report].

Erdei A, Steiber Z, Gazdag A, Bodor M, Berta E, Szász R, Szántó A, Ujhelyi B, Barna S, Berényi E, Nagy VE.

Orv Hetil. 2016 Feb 21;157(8):310-5. doi: 10.1556/650.2016.30381. Review. Hungarian.

PMID:
26876268
8.

[Treatment of acute myeloid leukemia -- a single center experience (2007-2013)].

Selmeczi A, Udvardy M, Illés A, Telek B, Kiss A, Batár P, Reményi G, Szász R, Ujj Z, Márton A, Ujfalusi A, Hevessy Z, Pinczés L, Bedekovics J, Rejtő L.

Orv Hetil. 2014 Apr 27;155(17):653-8. doi: 10.1556/OH.2014.29884. Hungarian.

PMID:
24755447
9.

[Waldenström macroglobulinemia].

Telek B, Batár P, Váróczy L, Gergely L, Rejtő L, Szász R, Miltényi Z, Simon Z, Udvardy M, Illés A.

Orv Hetil. 2013 Dec 1;154(50):1970-4. doi: 10.1556/OH.2013.29776. Hungarian.

PMID:
24317355
10.

Comparison of coated-platelet levels in patients with essential thrombocythemia with and without hydroxyurea treatment.

Reményi G, Szász R, Debreceni IB, Szarvas M, Batár P, Nagy B Jr, Kappelmayer J, Udvardy M.

Platelets. 2013;24(6):486-92. doi: 10.3109/09537104.2012.731112. Epub 2012 Dec 5.

PMID:
23216455
11.

Revised mechanism of complement lectin-pathway activation revealing the role of serine protease MASP-1 as the exclusive activator of MASP-2.

Héja D, Kocsis A, Dobó J, Szilágyi K, Szász R, Závodszky P, Pál G, Gál P.

Proc Natl Acad Sci U S A. 2012 Jun 26;109(26):10498-503. doi: 10.1073/pnas.1202588109. Epub 2012 Jun 12.

12.

[Current treatment of acute myeloid leukaemia in adults].

Telek B, Rejto L, Kiss A, Batár P, Reményi G, Szász R, Ujj ZÁ, Udvardy M.

Orv Hetil. 2012 Feb 19;153(7):243-9. doi: 10.1556/OH.2012.29304. Review. Hungarian.

PMID:
22318524
13.

[Practical considerations and questions in the treatment of chronic lymphocytic leukemia].

Telek B, Rejto L, Batár P, Reményi G, Szász R, Kiss A, Udvardy M.

Orv Hetil. 2011 Jun 12;152(24):958-63. doi: 10.1556/OH.2011.29135. Review. Hungarian.

PMID:
21609922
14.

Selective inhibition of the lectin pathway of complement with phage display selected peptides against mannose-binding lectin-associated serine protease (MASP)-1 and -2: significant contribution of MASP-1 to lectin pathway activation.

Kocsis A, Kékesi KA, Szász R, Végh BM, Balczer J, Dobó J, Závodszky P, Gál P, Pál G.

J Immunol. 2010 Oct 1;185(7):4169-78. doi: 10.4049/jimmunol.1001819. Epub 2010 Sep 3.

15.

[One hundred fifty autologous peripheral haemopoietic stem cell transplantations and their lessons].

Kiss A, Reményi G, Szász R, Batár P, Rejto L, Váróczy L, Sípos T, Kovácsné Kovács E, Szarvas M, Udvardy M.

Orv Hetil. 2009 Jul 5;150(27):1251-7. doi: 10.1556/OH.2009.28557. Hungarian.

PMID:
19531458
16.

[The pathophysiology, clinical signs and therapy of urate nephropathy].

Méhes L, Udvardy M, Szász R, Rejto L.

Orv Hetil. 2007 Apr 22;148(16):745-8. Review. Hungarian.

PMID:
17437951
17.

Coated-platelets retain amyloid precursor protein on their surface.

Prodan CI, Szasz R, Vincent AS, Ross ED, Dale GL.

Platelets. 2006 Feb;17(1):56-60.

PMID:
16308188
18.

Role of mitochondrial permeability transition pore in coated-platelet formation.

Remenyi G, Szasz R, Friese P, Dale GL.

Arterioscler Thromb Vasc Biol. 2005 Feb;25(2):467-71. Epub 2004 Dec 9.

PMID:
15591217
19.

COAT platelets.

Szasz R, Dale GL.

Curr Opin Hematol. 2003 Sep;10(5):351-5. Review.

PMID:
12913789
20.

Supplemental Content

Support Center